Key Developments: Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

52.53EUR
22 Aug 2014
Price Change (% chg)

€0.08 (+0.15%)
Prev Close
€52.45
Open
€52.22
Day's High
€52.89
Day's Low
€52.22
Volume
561,901
Avg. Vol
794,648
52-wk High
€54.32
52-wk Low
€46.64

Search Stocks

Latest Key Developments (Source: Significant Developments)

Fresenius Medical Care AG & Co KGaA confirms FY 2014 outlook
Thursday, 31 Jul 2014 01:22am EDT 

Fresenius Medical Care AG & Co KGaA:Confirms guidance for full FY 2014.Expects revenue to be at around $15.2 billion in FY 2014, translating into growth rate of around 4 pct.Says this outlook excludes revenue of about $500 million from acquisitions.Says net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be unchanged between $1.0 billion and $1.05 billion in FY 2014.FY 2014 revenue estimate $15.29 billion - Thomson Reuters I/B/E/S.  Full Article

Fresenius Medical Care AG & Co KGaA and Aetna Inc collaborate to provide coordinated care management for end stage renal disease patients
Tuesday, 10 Jun 2014 06:00am EDT 

Fresenius Medical Care AG & Co KGaA and Aetna Inc:Collaborative care model designed to improve quality of care for Aetna's Medicare Advantage members who have end stage renal disease, while lowering health care costs.  Full Article

Fresenius Medical Care AG & Co KGaA confirms its FY 2014 guidance in line with analysts estimates
Tuesday, 6 May 2014 01:38am EDT 

Fresenius Medical Care AG & Co KGaA:Expects revenue to be at around $15.2 billion in 2014, translating into a growth rate of around 4 pct, I/B/E/S Estimates revenue of $15.281 billion for 2014.Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014, I/B/E/S Estimates for 2014 net income of $1.120 billion.Expects to spend around $900 million on capital expenditures in 2014, I/B/E/S Estimates capex of $874.62 million for 2014.  Full Article

Fresenius Medical Care AG & Co KGaA and Joslin Diabetes Center Inc to work together to improve health of patients with diabetic kidney disease
Tuesday, 15 Apr 2014 02:28am EDT 

Fresenius Medical Care AG & Co KGaA:Says with Joslin Diabetes Center, Inc to jointly develop renal care programs in select Joslin Affiliated Centers for patients with diabetic kidney disease (DKD).Fresenius Medical Care and Joslin to jointly develop clinical guidelines and care delivery systems to manage high blood pressure, glucose, and nutrition in patients with DKD.In addition, organizations to help educate patients as they prepare for possibility of end stage renal disease (ESRD) and necessity for dialysis or kidney transplantation.  Full Article

Fresenius Medical Care AG & Co KGaA gives FY 2020 revenue guidance
Friday, 4 Apr 2014 02:28am EDT 

Fresenius Medical Care AG & Co KGaA:Announces its long-term financial target for FY 2020.Based on revenue of $14.6 billion in FY 2013, company has set its revenue guidance for FY 2020 at $28 billion.This represents a cumulative average growth rate of around 10 pct per annum (CAGR) and a near doubling of revenue compared to FY 2013.  Full Article

Fresenius Medical Care AG & Co KGaA proposes FY 2013 dividend
Tuesday, 25 Feb 2014 01:33am EST 

Fresenius Medical Care AG & Co KGaA:Proposes dividend of 0.77 euro per ordinary share for FY 2013.This is an increase of 3 pct from FY 2012 (0.75 euro per ordinary share).  Full Article

Fresenius Medical Care AG & Co KGaA issues FY 2014 outlook
Tuesday, 25 Feb 2014 12:58am EST 

Fresenius Medical Care AG & Co KGaA:Expects revenue to grow to approximately $15.2 billion in FY 2014.FY 2014 revenue of $15.347 billion - Thomson Reuters I/B/E/S.Net income attributable to shareholders is expected to be between $1.0 billion and $1.05 billion in FY 2014.FY 2014 net income of $1.178 billion - Thomson Reuters I/B/E/S.  Full Article

Fresenius Medical Care AG & Co KGaA Reconfirms Its FY 2013 Guidance In Line With Analysts' Estimates
Tuesday, 5 Nov 2013 01:50am EST 

Fresenius Medical Care AG & Co KGaA announced that it expects revenue to grow to more than USD 14.6 billion in 2013, translating into a growth rate of more than 6%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between USD 1.1 billion and USD 1.15 billion in 2013, likely at the low end of the range. For 2013, the Company expects to spend around USD 700 million on capital expenditures and around USD 500 million on acquisitions. The debt/EBITDA ratio is expected to be equal or below 3.0 by the end of 2013. According to I/B/E/S Estimates, analysts on average are expecting te Company to report for fiscal year 2013 revenues of USD 14.6 billion with a growth rate of 5.8%, net income of USD 1.104 billion and capital expenditures of USD 732.78 million.  Full Article

Fresenius Medical Care AG & Co KGaA's Spectra Laboratories, Inc Enters Acquisition Agreement with Shiel Medical Laboratory
Tuesday, 22 Oct 2013 08:30am EDT 

Spectra Laboratories, Inc., a subsidiary of Fresenius Medical Care AG & Co KGaA announced that it has signed a definitive agreement to acquire substantially all of the operating assets of Shiel Medical Laboratory, Inc., located in Brooklyn, New York. The acquisition will expand Spectra`s existing laboratory services capabilities in the metropolitan New York market and allow it to serve a broader base of health care providers and evolving health care delivery models. Purchase terms were not disclosed. The transaction is expected to close in the fourth quarter, 2013, pending regulatory approval.  Full Article

Fresenius Medical Care AG & Co KGaA Reaffirms FY 2013 Guidance-Conference Call
Wednesday, 31 Jul 2013 09:30am EDT 

Fresenius Medical Care AG & Co KGaA announced that its range continues to be greater than $14.6 billion in revenues or a 6% growth rate and a net income of $1.1 billion to $1.150 billion for fiscal 2013.  Full Article

UPDATE 2-Express Scripts drops Amgen anemia drugs from formulary

Aug 1 - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp, sold by Amgen Inc.

Search Stocks